Advertisement
CI vs CVS
Which Stock Would AI Choose? The Cigna Group (CI) vs. CVS Health (CVS) Stock Comparison
Key Takeaways
- CVS Health (CVS) has shown stronger recent momentum, with shares up approximately 12% over the past month compared to CI's 6% gain.
- CI reported Q1 earnings that beat estimates, driven by its Evernorth unit, but shares dipped amid plans to exit the Affordable Care Act marketplace by 2027.
- Year-to-date, CVS outperforms with about 5% gains versus CI's 3%, while over the past year CVS is up over 20% against CI's decline of around 15%.
- CVS offers a higher dividend yield at roughly 3.2%, compared to CI's 2.2%.
- Analysts have raised price targets for both post-recent developments, with CI targets around $330 and CVS near $97.
- Market caps differ, with CVS at $105 billion larger than CI's $75 billion.
Introduction
Both CI and CVS operate in the healthcare sector, with overlapping exposure to pharmacy benefit management (PBM), insurance, and services, making them natural comparables for investors navigating evolving regulations and consumer trends. CI, primarily focused on health insurance and PBM, contrasts with CVS's integrated model of retail pharmacy, PBM via Aetna, and health services. Traders seeking relative performance insights or sector positioning, especially amid recent earnings and policy shifts, will find this stock comparison valuable for assessing momentum, valuation, and market sentiment in the current environment.
CI Overview and Recent Performance
The Cigna Group (CI) is a global health services company emphasizing employer-sponsored health plans, Medicare Advantage, and its Evernorth health services division, including PBM operations. Shares trade around $283, within a 52-week range of $240 to $339, with a market capitalization of approximately $75 billion. In recent market activity, CI gained about 6% over the past month and 3% year-to-date (YTD), though down 15% over the past year. Q1 results showed revenue growth and adjusted earnings per share (EPS) of $7.79 beating estimates, bolstered by Evernorth, but shares fell on news of exiting the Affordable Care Act individual market by 2027—affecting 369,000 members—and softer PBM profits. Analyst targets have risen to $300-$340, signaling optimism on specialty pharmacy and cost controls, yet sentiment reflects caution over regulatory and competitive pressures.
CVS Overview and Recent Performance
CVS Health (CVS) integrates retail pharmacies, PBM through Caremark, and health insurance via Aetna, serving diverse segments from acute care to chronic management. Trading near $82, within a 52-week range of $58 to $85, its market cap stands at about $105 billion. Recent weeks saw robust gains of around 12-14% monthly and 5% YTD, with 22% over the past year, outperforming broader indices. Momentum stems from regulatory tailwinds enhancing Aetna and PBM visibility, alongside anticipation for Q1 earnings on May 6. The trailing price-to-earnings (P/E) ratio is elevated at 59 due to one-time items, but forward P/E is 11.5, with a 3.2% dividend yield supporting income focus. Investor sentiment benefits from diversified revenue and perceived value amid sector rotation.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 350 AI trading bots scanning thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML pattern recognition, technical analysis (TA), and fundamental analysis (FA), with timeframes from 5 minutes to days and risk tools such as 2-3% take-profit/stop-loss corridors. Standouts show annualized returns of 50-160%, win rates (profitable trade percentage) of 50-88%, and profit factors above 1.5-7, often beating the S&P 500 recently in themes like semiconductors, data centers, and industrials. For instance, semiconductor bots delivered up to 97% returns with 63% win rates. Explore these high-conviction, adaptive tools tailored to current conditions to enhance your trading edge.
Head-to-Head Comparison
CI and CVS share PBM and insurance exposure but diverge in business models: CI leans on employer plans and Evernorth services, while CVS adds retail pharmacy scale for resilient cash flows. Growth drivers differ—CI via specialty pharmacy expansion, CVS through Aetna synergies and health services. Recent momentum favors CVS with superior monthly and annual gains, versus CI's post-earnings pullback. Risk factors include regulatory scrutiny on PBMs for both, but CVS faces retail headwinds while CI navigates Medicare risks. CVS boasts higher yield and market cap; CI lower trailing P/E (12 vs. 59). Sentiment tilts positive for CVS on regulatory wins, CI on earnings upgrades.
Tickeron AI Verdict
Tickeron’s AI models would likely favor CVS in the current market, given its consistent upward trend, stronger relative performance over recent weeks and the past year, and positive catalysts like upcoming earnings and regulatory support. While CI shows stability via earnings beats and raised targets, CVS's momentum and positioning offer higher probability for near-term outperformance, based on trend analysis and sector dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CI is a Hold and CVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CI’s FA Score shows that 1 FA rating(s) are green whileCVS’s FA Score has 3 green FA rating(s).
- CI’s FA Score: 1 green, 4 red.
- CVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CI’s TA Score shows that 6 TA indicator(s) are bullish while CVS’s TA Score has 3 bullish TA indicator(s).
- CI’s TA Score: 6 bullish, 4 bearish.
- CVS’s TA Score: 3 bullish, 5 bearish.
Price Growth
CI (@Managed Health Care) experienced а +8.80% price change this week, while CVS (@Managed Health Care) price change was +8.45% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +14.45%. For the same industry, the average monthly price growth was +15.58%, and the average quarterly price growth was +29.25%.
Reported Earning Dates
CI is expected to report earnings on Jul 30, 2026.
CVS is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Managed Health Care (+14.45% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| CI | CVS | CI / CVS | |
| Capitalization | 78B | 124B | 63% |
| EBITDA | 12.1B | 11.1B | 109% |
| Gain YTD | 8.398 | 24.392 | 34% |
| P/E Ratio | 2.59 | 42.57 | 6% |
| Revenue | 268B | 408B | 66% |
| Total Cash | 7.8B | 11.8B | 66% |
| Total Debt | 30.9B | 78.3B | 39% |
CI | CVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 68 | 70 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 49 | 13 | |
P/E GROWTH RATING 1..100 | 99 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (3) in the Drugstore Chains industry is in the same range as CI (5) in the Managed Health Care industry. This means that CVS’s stock grew similarly to CI’s over the last 12 months.
CI's Profit vs Risk Rating (68) in the Managed Health Care industry is in the same range as CVS (70) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CI's SMR Rating (100) in the Managed Health Care industry is in the same range as CVS (100) in the Drugstore Chains industry. This means that CI’s stock grew similarly to CVS’s over the last 12 months.
CVS's Price Growth Rating (13) in the Drugstore Chains industry is somewhat better than the same rating for CI (49) in the Managed Health Care industry. This means that CVS’s stock grew somewhat faster than CI’s over the last 12 months.
CVS's P/E Growth Rating (5) in the Drugstore Chains industry is significantly better than the same rating for CI (99) in the Managed Health Care industry. This means that CVS’s stock grew significantly faster than CI’s over the last 12 months.
| CI | CVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 60% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 57% | 1 day ago 65% |
| Momentum ODDS (%) | 1 day ago 60% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 59% |
| Advances ODDS (%) | 1 day ago 63% | 2 days ago 66% |
| Declines ODDS (%) | 7 days ago 56% | 8 days ago 60% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 63% | 1 day ago 67% |
Advertisement
CI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.
CVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CVS has been loosely correlated with UNH. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CVS jumps, then UNH could also see price increases.